PROSTATE WARRIORS - The latest news about prostate cancer
  • Home
  • Cancer 1O1
  • News
  • Navigator
  • Newsletters
  • Contact
  • Search
  • Menu Menu

VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer

January 14, 2025/0 Comments/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-14 09:27:162025-01-14 09:27:16VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer

Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer

January 14, 2025/0 Comments/in Immunotherapy, Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-14 09:08:582025-01-14 09:15:31Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer

RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy

January 14, 2025/0 Comments/in Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-14 08:56:492025-01-14 08:56:49RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy

Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer

January 14, 2025/0 Comments/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-14 08:29:352025-01-14 08:29:35Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer

Results from Phase 3 Trial of CAN-2409: a Promising Immunotherapy for Prostate Cancer

January 14, 2025/0 Comments/in Clinical Trial, Localized/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-14 07:58:512025-01-14 08:04:28Results from Phase 3 Trial of CAN-2409: a Promising Immunotherapy for Prostate Cancer

Phase 3 Trial of BMS-986365

January 13, 2025/0 Comments/in Clinical Trial, Metastatic, Phase 3/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-13 07:55:262025-01-13 07:43:20Phase 3 Trial of BMS-986365

A New Hope for Aggressive Prostate Cancer: Evexomostat’s Potential

January 12, 2025/0 Comments/in Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-12 08:42:362025-01-12 08:42:36A New Hope for Aggressive Prostate Cancer: Evexomostat’s Potential

NXP800: A Promising New Drug for Hormone-Resistant Prostate Cancer

January 12, 2025/0 Comments/in Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-12 08:31:312025-01-12 08:31:31NXP800: A Promising New Drug for Hormone-Resistant Prostate Cancer
Page 1 of 15123›»

Menu

  • Home
  • Cancer 1O1
  • News
  • Navigator
  • Newsletters
  • Contact

Categories

Archives

  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • September 2023

Tags

abiraterone acetate ADT alphafold androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody bone metastases BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide diet docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer metformin mHSPC neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial survival outcomes T-cell therapy theranostics treatment resistance

Latest Posts

  • VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer January 14, 2025
  • Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer January 14, 2025
  • RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy January 14, 2025
  • Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer January 14, 2025
© Copyright 2024 - PROSTATE WARRIORS - The latest news about prostate cancer
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only